Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

NCT01516762 | Unknown

• 2 other identifiers: 159952011-004469-33
• Study Type: expanded_access
• Target: N/A
• Locations: 1 country
• Sites: 60

Brief Summary

This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC patients diagnosed with symptomatic bone metastasis and to collect additional short and long term safety data on the product.

Conditions

Prostatic Neoplasms

Keywords

Radium 223; Alpharadin; Prostate Cancer; Bone metastases; Castrate resistant prostate cancer; Hormone refractory prostate cancer

Interventions

Radium-223 dichloride (BAY88-8223) DRUG

One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years
• Histologically or cytologically confirmed prostate cancer
• Patients diagnosed with symptomatic progressive bone predominant metastatic CRPC/HRPC with at least 2 skeletal metastases on imaging with no lung, liver, and/or brain metastasis (lymph node only metastasis is allowed)
• Symptomatic is defined as either
• Regular (not occasional) use of analgesic medication for cancer related bone pain (≥ level 1; World Health Organization \[WHO\] ladder for cancer pain), or
• Treatment with external beam radiation therapy (EBRT) for bone pain (the EBRT should be within the last 12 weeks before treatment)
• Progressive disease is defined either by:
• The appearance of new bone lesions. If progression is based on new lesion(s) on imaging only without an increase in prostate specific antigen (PSA), then PSA values from 3 assessments within the last 6 months must be provided; OR
• In the absence of new bone lesions, 2 subsequent increases in serum PSA over previous reference value, which should not be more than 6 months before screening, each measured at least 1 week apart with the last PSA ≥ 5 ng/mL. (The reference value time point 1, is defined as the last PSA measured before increases are documented, with subsequent values obtained a minimum of 1 week apart. If the PSA at time point 3 is greater than the PSA at time point 2, then eligibility has been met. If the PSA at time point 3 is not greater than the PSA at time point 2 but, the PSA value at time point 4 and/or time point 5 is greater than the PSA at time point 2, the patient is eligible assuming that other criteria are met).
• No intention to use cytotoxic chemotherapy within the next 6 months
• Life expectancy ≥ 6 months
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2
• Adequate hematological, liver, and renal function
• Absolute neutrophil count (ANC) ≥ 1.5 x10\^9/L
• Platelet count ≥ 100 x10\^9/L

You may not qualify if:

• Treatment with an investigational drug within previous 4 weeks, or planned during the treatment period or follow-up
• Eligible for first course of docetaxel, i.e., patients who are fit enough, willing, and who are located where treatment with docetaxel is available
• Treatment with cytotoxic chemotherapy within previous 4 weeks prior to screening, or failure to recover from adverse events (AEs) due to cytotoxic chemotherapy administered more than 4 weeks previous prior to screening (however, ongoing neuropathy is permitted)
• Prior hemibody external radiotherapy is excluded. Patients who received other types of prior external radiotherapy are allowed provided that the bone marrow function is assessed and meets the protocol requirements for hemoglobin, absolute neutrophil count, and platelets
• Received systemic therapy with radionuclides (e.g., strontium-89, samarium-153, rhenium-186, or rhenium-188, or radium-223 dichloride) for the treatment of bony metastases
• Other malignancy treated within the last 3 years (except non melanoma skin cancer or low-grade superficial bladder cancer)
• Visceral metastases as assessed by abdominal or pelvic computed tomography (CT) (or other imaging modality based on institutional standard of care)
• Presence of brain metastases
• Lymphadenopathy exceeding 6 cm in short-axis diameter
• Any size pelvic lymphadenopathy if it is thought to be a contributor to concurrent hydronephrosis.
• Imminent spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI). Patients with history of spinal cord compression should have completely recovered.
• Any other serious illness or medical condition, such as but not limited to:
• Any infection ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 Grade 2
• Cardiac Failure New York Heart Association (NYHA) Class III or IV
• Crohn's disease or ulcerative colitis

Sponsors & Collaborators

• Bayer: lead

Study Sites (60)

Unknown Facility

Birmingham, Alabama, 35233, United States

Location

Unknown Facility

Phoenix, Arizona, 85040, United States

Location

Unknown Facility

Scottsdale, Arizona, 85260, United States

Location

Unknown Facility

Greenbrae, California, 94904, United States

Location

Unknown Facility

La Jolla, California, 92093, United States

Location

Unknown Facility

San Francisco, California, 94143, United States

Location

Unknown Facility

Stanford, California, 94305, United States

Location

Unknown Facility

Aurora, Colorado, 80045, United States

Location

Unknown Facility

Newark, Delaware, 19718, United States

Location

Unknown Facility

Washington D.C., District of Columbia, 20007, United States

Location

Unknown Facility

Washington D.C., District of Columbia, 20060, United States

Location

Unknown Facility

Fort Myers, Florida, 33901, United States

Location

Unknown Facility

Miami Beach, Florida, 33140, United States

Location

Unknown Facility

Tampa, Florida, 33612, United States

Location

Unknown Facility

Atlanta, Georgia, 30322, United States

Location

Unknown Facility

Honolulu, Hawaii, 96813-2413, United States

Location

Unknown Facility

Goshen, Indiana, 46526, United States

Location

Unknown Facility

Iowa City, Iowa, 52242, United States

Location

Unknown Facility

New Orleans, Louisiana, 70112, United States

Location

Unknown Facility

Shreveport, Louisiana, 71103, United States

Location

Unknown Facility

Baltimore, Maryland, 21201-1595, United States

Location

Unknown Facility

Baltimore, Maryland, 21229, United States

Location

Unknown Facility

Baltimore, Maryland, 21287, United States

Location

Unknown Facility

Bethesda, Maryland, 20889, United States

Location

Unknown Facility

Rockville, Maryland, 20850, United States

Location

Unknown Facility

Boston, Massachusetts, 02114, United States

Location

Unknown Facility

Boston, Massachusetts, 02215, United States

Location

Unknown Facility

Ann Arbor, Michigan, 48109-0028, United States

Location

Unknown Facility

Detroit, Michigan, 48201, United States

Location

Unknown Facility

Detroit, Michigan, 48202, United States

Location

Unknown Facility

Minneapolis, Minnesota, 55455, United States

Location

Unknown Facility

St Louis, Missouri, 63110, United States

Location

Unknown Facility

Las Vegas, Nevada, 89169, United States

Location

Unknown Facility

New Brunswick, New Jersey, 08903-2681, United States

Location

Unknown Facility

Newark, New Jersey, 07103, United States

Location

Unknown Facility

New Hyde Park, New York, 11040-1496, United States

Location

Unknown Facility

New York, New York, 10016, United States

Location

Unknown Facility

New York, New York, 10065, United States

Location

Unknown Facility

Syracuse, New York, 13210, United States

Location

Unknown Facility

Durham, North Carolina, 27710, United States

Location

Unknown Facility

Raleigh, North Carolina, 27607, United States

Location

Unknown Facility

Cleveland, Ohio, 44195, United States

Location

Unknown Facility

Columbus, Ohio, 43212, United States

Location

Unknown Facility

Springfield, Oregon, 97477, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19107, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19111-2497, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19401, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, 15213, United States

Location

Unknown Facility

Myrtle Beach, South Carolina, 29572, United States

Location

Unknown Facility

Myrtle Beach, South Carolina, 29577, United States

Location

Unknown Facility

Nashville, Tennessee, 37232, United States

Location

Unknown Facility

Houston, Texas, 77030, United States

Location

Unknown Facility

Plano, Texas, 75093, United States

Location

Unknown Facility

San Antonio, Texas, 78229, United States

Location

Unknown Facility

Temple, Texas, 76508, United States

Location

Unknown Facility

Hampton, Virginia, 23666, United States

Location

Unknown Facility

Norfolk, Virginia, 23507, United States

Location

Unknown Facility

Seattle, Washington, 98122, United States

Location

Unknown Facility

Wheeling, West Virginia, 26003, United States

Location

Unknown Facility

Milwaukee, Wisconsin, 53226-3596, United States

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

radium Ra 223 dichloride

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Bayer Study Director

  Bayer

  STUDY DIRECTOR

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 20, 2012
• First Posted: January 25, 2012
• Last Updated: July 14, 2014

Record last verified: 2014-07

Locations

US (60)